Cognition Therapeutics Announces New Conversations Episode on Therapeutic Strategies to Protect the Retina in Dry AMD
07 Setembro 2023 - 8:45AM
Cognition Therapeutics, Inc., (Nasdaq: CGTX), (the “Company” or
“Cognition”) has released its sixth “Conversations” video podcast,
which features an interactive discussion with retinal specialists
about dry age-related macular degeneration (dry AMD) and the
current treatment landscape. Dry AMD is caused by a degeneration of
the macula and gradual loss of central vision. An estimated 1.5
million people in the United States are affected by late-stage dry
AMD, which can result in permanent vision loss.
C. Gustavo De Moraes, M.D., Ph.D., MPH, associate professor of
clinical ophthalmology at Columbia University and chief medical
officer of Ora, a CRO focused on ophthalmology, moderates this
discussion of the pathologic drivers of dry AMD, the treatment
landscape, clinical rationale for sigma-2 (σ-2) receptor modulators
and the ongoing MAGNIFY phase 2 trial of CT1812 in geographic
atrophy secondary to dry AMD. Panelists include Anthony Caggiano,
M.D., Ph.D., Cognition Therapeutics’ chief medical officer and two
leading industry experts on research and treatment of retinal
disease.
Episode 6: “Geographic Atrophy: New Strategies to Protect the
Retina” features:
- Jeffrey S. Heier, M.D., Director of the Vitreoretinal Service
& Retina Research at Ophthalmic Consultants of Boston
- Peter K. Kaiser, M.D., FASRS, Chaney Family Endowed Chair in
Ophthalmology Research and Professor of Ophthalmology at the
Cleveland Clinic Lerner College of Medicine
Cognition Therapeutics welcomes comments, questions and feedback
on this and other Conversations episodes which may be submitted at
conversations@cogrx.com. We’d love to hear your thoughts.
About CT1812CT1812 is an experimental orally
delivered small molecule sigma-2 (σ-2) receptor modulator designed
to penetrate the blood-retinal barrier and bind selectively and
saturably to the σ-2 receptor complex. The σ-2 receptor complex is
involved in the regulation of key cellular processes such as
membrane trafficking and autophagy that are damaged by toxic
interaction with soluble beta amyloid (Aβ) oligomers, oxidative
stress and other stressors. Cognition’s clinical program will
assess if regulating these processes by modulating the σ-2 receptor
with CT1812 can maintain homeostatic function.
About Geographic Atrophy Secondary to Dry
AMDDry AMD, one of two forms of AMD, is common among
people over 50 and is caused by degeneration and thinning of the
macula, the part of the retina responsible for central vision. The
gradual loss of central vision associated with dry AMD can present
limitations in reading and driving. As the disease progresses in
severity into geographic atrophy, degeneration of retinal pigment
epithelial (RPE) cells can result in permanent vision loss.
About Cognition Therapeutics, Inc.Cognition
Therapeutics, Inc. is a clinical-stage biopharmaceutical company
engaged in the discovery and development of innovative, small
molecule therapeutics targeting age-related degenerative disorders
of the central nervous system and retina. We are currently
investigating our lead candidate CT1812 in clinical programs in
Alzheimer’s disease, dementia with Lewy bodies (DLB) and dry
age-related macular degeneration (dry AMD). We believe CT1812 and
our pipeline of σ-2 receptor modulators can regulate pathways that
are impaired in these diseases. We believe that targeting the σ-2
receptor with CT1812 represents a mechanism functionally distinct
from other current approaches in clinical development for the
treatment of degenerative diseases. More about Cognition
Therapeutics and its pipeline can be found
at https://cogrx.com
Health Care Disclaimer Our podcast series does
not constitute the practice of medical advice, diagnosis or
treatment. Always talk to your health care provider for diagnosis
and treatment, including your specific medical needs. If you have
or suspect that you have a medical problem or condition, please
contact a qualified health care professional immediately.
Forward-Looking StatementsThis press release
contains forward-looking statements within the meaning of The
Private Securities Litigation Reform Act of 1995. All statements
contained in this press release, other than statements of
historical facts or statements that relate to present facts or
current conditions, are forward-looking statements. These
statements, including statements relating to the timing and
expected results of our clinical trials, and cash runway, involve
known and unknown risks, uncertainties and other important factors
that may cause our actual results, performance, or achievements to
be materially different from any future results, performance, or
achievements expressed or implied by the forward-looking
statements. In some cases, you can identify forward-looking
statements by terms such as “may,” might,” “will,” “should,”
“expect,” “plan,” “aim,” “seek,” “anticipate,” “could,” “intend,”
“target,” “project,” “contemplate,” “believe,” “estimate,”
“predict,” “forecast,” “potential” or “continue” or the negative of
these terms or other similar expressions. We have based these
forward-looking statements largely on our current expectations and
projections about future events and financial trends that we
believe may affect our business, financial condition, and results
of operations. These forward-looking statements speak only as of
the date of this press release and are subject to a number of
risks, uncertainties and assumptions, some of which cannot be
predicted or quantified and some of which are beyond our control.
Factors that may cause actual results to differ materially from
current expectations include, but are not limited to: competition;
our ability to secure new (and retain existing) grant funding; our
ability to grow and manage growth, maintain relationships with
suppliers and retain our management and key employees; our ability
to successfully advance our current and future product candidates
through development activities, preclinical studies and clinical
trials and costs related thereto; uncertainties inherent in the
results of preliminary data and pre-clinical studies being
predictive of the results of clinical trials; the timing, scope and
likelihood of regulatory filings and approvals, including
regulatory approval of our product candidates; changes in
applicable laws or regulations; the possibility that the we may be
adversely affected by other economic, business or competitive
factors, including ongoing economic uncertainty; our estimates of
expenses and profitability; the evolution of the markets in which
we compete; our ability to implement our strategic initiatives and
continue to innovate our existing products; our ability to defend
our intellectual property; the impact of the ongoing COVID-19
pandemic on our business, supply chain and labor force; and the
risks and uncertainties described in the “Risk Factors” section of
our annual and quarterly reports filed the Securities Exchange
Commission. These risks are not exhaustive and we face both known
and unknown risks. You should not rely on these forward-looking
statements as predictions of future events. The events and
circumstances reflected in our forward-looking statements may not
be achieved or occur, and actual results could differ materially
from those projected in the forward-looking statements. Moreover,
we operate in a dynamic industry and economy. New risk factors and
uncertainties may emerge from time to time, and it is not possible
for management to predict all risk factors and uncertainties that
we may face. Except as required by applicable law, we do not plan
to publicly update or revise any forward-looking statements
contained herein, whether as a result of any new information,
future events, changed circumstances or otherwise.
Contact Information:Cognition Therapeutics,
Inc. info@cogrx.com
Bill Borden (media) Tiberend Strategic Advisors,
Inc.bborden@tiberend.com
Daniel Kontoh-Boateng (investors) Tiberend Strategic
Advisors, Inc. dboateng@tiberend.com
Cognition Therapeutics (NASDAQ:CGTX)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
Cognition Therapeutics (NASDAQ:CGTX)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024